284 Differential Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

European Journal of Cancer - United Kingdom
doi 10.1016/s0959-8049(12)72082-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Corrigendum: Blocking C-Met–mediated PARP1 Phosphorylation Enhances Anti-Tumor Effects of PARP Inhibitors

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2016English

MA22.01 PARP Inhibitor Radiosensitization of Small Cell Lung Cancer Differs by PARP Trapping Potency

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Proteome-Wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets

Cell Chemical Biology
Molecular MedicineMolecular BiologyPharmacologyBiochemistryClinical BiochemistryDrug Discovery
2016English

The Multifunctional Protein YB-1 Potentiates PARP1 Activity and Decreases the Efficiency of PARP1 Inhibitors

Oncotarget
Oncology
2018English

PARP Inhibitors in Ovarian Cancer

2013English

Homologous Repair Deficiencies and Current Insights in Clinical Evaluation of PARP Inhibitors in Prostate Cancer

Memo - Magazine of European Medical Oncology
OncologyHematology
2020English

PARP Inhibitors and Stratified Treatment of Prostate Cancer

Expert Review of Anticancer Therapy
OncologyPharmacology
2016English

Resistance to PARP Inhibitors by SLFN11 Inactivation Can Be Overcome by ATR Inhibition

Oncotarget
Oncology
2016English

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Cancer Cell
Cancer ResearchOncologyCell Biology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy